<DOC>
	<DOCNO>NCT00001250</DOCNO>
	<brief_summary>Patients untreated clinical stage II breast cancer eligible . An excisional biopsy primary tumor acceptable , without definitive local therapy prior chemotherapy . Histologic confirmation invasive carcinoma require . Patients prospectively randomize receive five 21-day cycle dose-intense ( 5-fluorouracil , adriamycin , leucovorin , cytoxan , granuloctye-colony stimulating factor [ FLAC/G-CSF ] ) chemotherapy either ( preoperative ) ( postoperative ) local therapy . Chemotherapy give outpatient . For patient receive preoperative chemotherapy , local therapy ( modified radical mastectomy , breast segmentectomy/axillary dissection/breast radiotherapy accord patient preference ) perform 3-4 week last chemotherapy . For patient receive postoperative chemotherapy , chemotherapy begin 2-3 week local therapy . Immediate reconstruction mastectomy acceptable . Upon completion local therapy chemotherapy either treatment group , estrogen receptor positive patient receive tamoxifen 5 year . Follow-up consist history physical examination 3 month first 3 year , six month year 4 5 , yearly thereafter . Mammogram , bone scan , chest x-ray blood work perform yearly .</brief_summary>
	<brief_title>Effect Preoperative Chemotherapy Axillary Lymph Node Metastases Stage II Breast Cancer : A Prospective Randomized Trial</brief_title>
	<detailed_description>A prospective randomize trial evaluate effect preoperative dose intense chemotherapy ( FLAC/G-CSF ) axillary lymph node metastasis woman clinical stage II ( T1N1 , T2N0 , T2N1 ) breast cancer . Patients randomize receive 5 cycle combination chemotherapy ( 5-FU , adriamycin , leucovorin , cytoxan , G-CSF ) either initial therapy ( preoperative ) postoperatively local therapy ( modified radical mastectomy lumpectomy/axillary lymph node dissection/whole breast radiotherapy ) . Each chemotherapy cycle 21 day . At time local therapy incidence axillary metastasis axillary dissection specimen determine compare preoperative chemotherapy vs. postoperative chemotherapy treatment group .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>INCLUSION CRITERIA Women age clinical stage II breast cancer meet follow criterion : Patients stage II breast cancer include primary tumor less equal 5 cm size axillary lymph node clinically ( [ N0 N1 ] [ T1N1 , T2N0 , T2N1 ] ) . Patients stag accord 1986 AJCC TMM classification . Patients bilateral breast cancer eligible provide least one tumor invasive classified stage I II , neither breast stage III . Histologic section breast tumor must classify invasive primary breast neoplasm epithelial origin . Patients must geographically accessible followup willing return followup NCI . Patients must mentally competent understand give inform consent protocol . Estrogen receptor ( ER ) status include ER positive , negative , unknown . Patients prior cancer may eligible long received curative therapy evidence recurrence great equal 10 year . EXCLUSION CRITERIA Patients exclude protocol follow reason : Advanced local disease distant metastasis ( stage III IV ) . Previous therapy breast excisional biopsy . Pregnancy . Unwillingness use birth control chemotherapy . Chronic disease heart , lung , liver , kidney , blood metabolic disorder may render patient poor risk surgery chemotherapy . Specifically , liver function SGOT , SGPT , alkaline phosphatase total bilirubin le 1.5 x upper limit normal . Renal function creatinine le 1.7 and/or creatinine clearance great 45 ml/min . If history cardiac disease , patient must normal ejection fraction MUGA scan angina .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>Dose Intense Chemotherapy</keyword>
	<keyword>Stage II Breast Cancer</keyword>
	<keyword>Early Stage Breast Cancer</keyword>
</DOC>